Applications of the genO‑hPD‑1/hTIM3 mouse model

Useful applications for researchers working on different biomedical fields, such as immuno-oncology, immuno-inflammation and autoimmunity:

  • Assess the efficacy of PD-1 and/or TIM3-targeting compounds
    • Perform tumor growth inhibition assays in the context of monotherapies or combotherapies
    • Identify new possible therapies
  • Gain insights into the mechanism of action (MOA) of diverse constructs and their potential therapeutic benefits

Features

  • Physiological regulation and expression pattern of human PD-1 and human TIM3
  • Preservation of the target-ligand interactions
  • Fully functional mouse immune system
  • Lack of expression of the murine target genes

Clients

No items found.

Model Delivery & Logistics

  • Breeding facilities in the US and Europe through our trusted partners:
  • Quick, compliant, and reliable door-to-door delivery worldwide
  • Models with certified SOPF health status from AAALAC-accredited and PHS-assured professional breeders in the US and Europe

Validation data

Discover related products to

genO-hPD‑1/hTIM3

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
CD47
SIRPα
ICP (single-target)
ICP (multi-target)
Immune checkpoint

genO-hCD47/hSIRPα

Double-humanized genO‑hCD47/hSIRPα immunocompetent mice enable the efficacy assessment of anti-CD47/SIRPα.

Immune checkpoint
CTLA-4
ICP (single-target)

genO-hCTLA‑4

The genO‑hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)

genO-hCTLA‑4/hLAG3

The genO‑hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
OX40
ICP (single-target)

genO-hOX40

The genO-hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

genO-hPD‑1/hCTLA‑4

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

genO-hPD‑1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

genO-hPD‑1/hPD‑L1

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

genO-hPD‑1/hVISTA

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

CD137
ICP (single-target)
Immune checkpoint

genO‑hCD137

genO‑hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137.

Immune checkpoint
CD28
ICP (single-target)
T-cell engager

genO‑hCD28

The genO‑hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CD39
ICP (single-target)

genO‑hCD39

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)

genO‑hGITR

The genO‑hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)

genO‑hGITR/hGITRL

The genO‑hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

PD-1
Immune checkpoint
ICP (single-target)

genO‑hPD‑1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

genO‑hPD‑1/hLAG3

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
VISTA
ICP (single-target)

genO‑hVISTA

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

PD-L1
Immune checkpoint
MC38
PD-1

genO-MC38-hPD-L1-LZ

The genO-MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

Preclinical double-humanized genO‑hPD‑1/hTIM3mouse model

Get in touch about

Let us know how we can help

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe